Bicara Therapeutics
Vice President, Global Advocacy and Community Engagement
Bicara Therapeutics, Boston, Massachusetts, us, 02298
Vice President, Global Advocacy and Community Engagement
Position Overview
Bicara Therapeutics is seeking a Vice President of Global Advocacy and Community Engagement to lead and expand our patient, provider, and community engagement strategy as we transition from a clinical‑stage company into early commercialization. Reporting to the Chief Corporate Affairs Officer, this individual will play a key role in ensuring the patient perspective informs clinical development, launch planning, and access strategy.
The ideal candidate brings experience working in small biotech and has supported a company during its transition from late‑stage clinical to commercial. They will have deep oncology expertise, particularly in head and neck cancer or other solid tumors such as colorectal cancer, and a strong track record of partnering with advocacy groups and internal cross‑functional teams to ensure patient‑centered progress.
This role is based in our Boston office and follows a hybrid schedule, with three in‑office days each week.
Responsibilities
Lead the development and execution of Bicara’s global advocacy strategy to support clinical milestones and pre‑commercial readiness.
Build and sustain trusted partnerships with patient advocacy organizations, non‑profits, caregivers, and clinical stakeholders in head and neck cancer and other solid tumor areas.
Collaborate cross‑functionally with Clinical Development, Medical Affairs, and Commercial teams to integrate patient insights into trial design, go‑to‑market strategies, and launch communications.
Co‑create patient education, disease awareness, and access‑focused initiatives in partnership with advocacy organizations.
Serve as Bicara’s representative at key advocacy, policy, and community engagement events; advise on opportunities to amplify the patient voice throughout the commercialization process.
Establish feedback mechanisms to inform commercial strategy, including patient‑reported outcomes and unmet need insights.
Develop measurable objectives to demonstrate the impact of advocacy efforts and report progress to senior leadership.
Qualifications
10+ years of experience in patient advocacy, public affairs, or related functions within biotech or pharmaceutical companies.
Proven experience in a late‑stage clinical or early commercial biotech environment, ideally during a product launch or pre‑launch phase.
Oncology background required, with strong preference for head and neck cancer or solid tumor (e.g., colorectal cancer) experience.
Demonstrated ability to build and scale advocacy programs during periods of growth and organizational change.
Strong communication and relationship‑building skills with the ability to influence internal and external stakeholders.
Strategic mindset with an operational, hands‑on approach. Must be comfortable working in a lean, fast‑moving environment.
Passion for elevating the patient voice and improving health equity and access.
Established relationships with advocacy organizations in oncology, especially those focused on head and neck or GI cancers.
Familiarity with patient input integration into regulatory submissions, HTA bodies, and access frameworks.
Experience developing programs that align with commercial planning, including disease awareness, trial readiness, and post‑launch support.
Company Overview Bicara Therapeutics is a clinical‑stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF‑β). Through this dual‑targeting mechanism, ficerafusp alfa has the potential to exert potent anti‑tumor activity by simultaneously blocking both cancer cell‑intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF‑β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Here at Bicara, we believe in building diverse teams and cultivating a culture where all voices are included. We encourage people from all backgrounds to apply.
Bicara Therapeutics is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.
#J-18808-Ljbffr
The ideal candidate brings experience working in small biotech and has supported a company during its transition from late‑stage clinical to commercial. They will have deep oncology expertise, particularly in head and neck cancer or other solid tumors such as colorectal cancer, and a strong track record of partnering with advocacy groups and internal cross‑functional teams to ensure patient‑centered progress.
This role is based in our Boston office and follows a hybrid schedule, with three in‑office days each week.
Responsibilities
Lead the development and execution of Bicara’s global advocacy strategy to support clinical milestones and pre‑commercial readiness.
Build and sustain trusted partnerships with patient advocacy organizations, non‑profits, caregivers, and clinical stakeholders in head and neck cancer and other solid tumor areas.
Collaborate cross‑functionally with Clinical Development, Medical Affairs, and Commercial teams to integrate patient insights into trial design, go‑to‑market strategies, and launch communications.
Co‑create patient education, disease awareness, and access‑focused initiatives in partnership with advocacy organizations.
Serve as Bicara’s representative at key advocacy, policy, and community engagement events; advise on opportunities to amplify the patient voice throughout the commercialization process.
Establish feedback mechanisms to inform commercial strategy, including patient‑reported outcomes and unmet need insights.
Develop measurable objectives to demonstrate the impact of advocacy efforts and report progress to senior leadership.
Qualifications
10+ years of experience in patient advocacy, public affairs, or related functions within biotech or pharmaceutical companies.
Proven experience in a late‑stage clinical or early commercial biotech environment, ideally during a product launch or pre‑launch phase.
Oncology background required, with strong preference for head and neck cancer or solid tumor (e.g., colorectal cancer) experience.
Demonstrated ability to build and scale advocacy programs during periods of growth and organizational change.
Strong communication and relationship‑building skills with the ability to influence internal and external stakeholders.
Strategic mindset with an operational, hands‑on approach. Must be comfortable working in a lean, fast‑moving environment.
Passion for elevating the patient voice and improving health equity and access.
Established relationships with advocacy organizations in oncology, especially those focused on head and neck or GI cancers.
Familiarity with patient input integration into regulatory submissions, HTA bodies, and access frameworks.
Experience developing programs that align with commercial planning, including disease awareness, trial readiness, and post‑launch support.
Company Overview Bicara Therapeutics is a clinical‑stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors. Bicara’s lead program, ficerafusp alfa, is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF‑β). Through this dual‑targeting mechanism, ficerafusp alfa has the potential to exert potent anti‑tumor activity by simultaneously blocking both cancer cell‑intrinsic EGFR survival and proliferation, as well as the immunosuppressive TGF‑β signaling within the tumor microenvironment. Ficerafusp alfa is being developed in head and neck squamous cell carcinoma, where there remains a significant unmet need, as well as other solid tumor types. For more information, please visit www.bicara.com or follow us on LinkedIn or X.
Here at Bicara, we believe in building diverse teams and cultivating a culture where all voices are included. We encourage people from all backgrounds to apply.
Bicara Therapeutics is an equal opportunity employer and will not discriminate against any employee or applicant on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, veteran status, or any classification protected by federal, state, or local law.
#J-18808-Ljbffr